News

Sant Pau initiates the second clinical trial on the long-term effects of deep brain stimulation (DBS) in patients with ultra-resistant schizophrenia to treatment

Sant Pau continues to lead in the treatment of pharmacoresistant schizophrenia with deep brain stimulation (DBS) worldwide. After performing the first intervention of this kind in 2014 and publishing ...

S’s Scientific-Technical Service Platforms successfully achieve ISO 9001 audit

Once again, the Scientific-Technical Service Platforms (PSCT) of the Sant Pau Research Institute and Sant Pau Hospital have successfully passed the ISO 9001 Quality Management System audit, demonstrat...

The Sant Pau Research Day on genomics and rare diseases was successfully celebrated today

Today, we celebrated the Sant Pau Research Day with genomics and rare diseases taking center stage. The day began with an introduction by Dr. Xavier Prats Monné, president of the board of the Sant Pa...

La lisil oxidasa, clau per combatre la calcificació cardiovascular

A study led by Dr. José Martínez-González, a researcher at Sant Pau Research Institute and the Biomedical Research Institute of Barcelona (IIBB-CSIC), and Dr. Cristina Rodríguez, head of the Cardi...

Dr. Silvia Vidal discusses immunological mechanisms in multiple myeloma with anti-CD38 antibodies

Dr. Silvia Vidal, head of the Inflammatory Diseases group at the Sant Pau Research Institute, participated in the "Immunotherapy & Hemopathies 2023" course, where she spoke about the immunological...